ResMed (NYSE:RMD) CEO Sells $1,252,890.73 in Stock

ResMed (NYSE:RMD) CEO Michael Farrell sold 4,991 shares of the company’s stock on March 9th for over $1.25 million, reducing his stake by about 1.06%. This sale occurred shortly after ResMed reported stronger-than-expected quarterly earnings and declared a quarterly dividend. The stock currently holds a “Moderate Buy” consensus rating from analysts, with a consensus target price of $299.27.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin